<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1502210515
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Vildus 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VILDAGLIPTIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        33.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BH02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>medicines called &ldquo;oral antidiabetics&rdquo;.<br />Vildus&trade; is used to treat adult patients with type 2 diabetes. It is used when<br />diabetes cannot be controlled by diet and exercise alone. It helps to control<br />the level of sugar in the blood. Your doctor will prescribe Vildus&trade; either<br />alone or together with certain other antidiabetic medicines which you will<br />already be taking, if these have not proved sufficiently effective to control<br />diabetes.<br />Type 2 diabetes develops if the body does not make enough insulin or if the<br />insulin that the body makes does not work as well as it should. It can also<br />develop if the body produces too much glucagon.<br />Insulin is a substance which helps to lower the level of sugar in the blood,<br />especially after meals. Glucagon is a substance which triggers the production<br />of sugar by the liver, causing the blood sugar level to rise. The pancreas<br />makes both of these substances.<br />How Vildus&trade; works<br />Vildus&trade; works by making the pancreas produce more insulin and less<br />glucagon. This helps to control the blood sugar level. This medicine has been<br />shown to reduce blood sugar, which may help to prevent complications from<br />your diabetes. Even though you are now starting a medicine for your<br />diabetes, it is important that you continue to follow the diet and/or exercise<br />which has been recommended for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Vildus&trade;:<br />&bull; if you are allergic to vildagliptin or any of the other ingredients of this<br />medicine (listed in section 6). If you think you may be allergic to vildagliptin<br />or any of the other ingredients of Vildus&trade;, do not take this medicine and<br />talk to your doctor.<br />Warnings and precautions<br />Talk to your doctor, pharmacist or nurse before taking Vildus&trade;<br />&bull; if you have type 1 diabetes (i.e. your body does not produce insulin) or if<br />you have a condition called diabetic ketoacidosis.<br />&bull; if you are taking an anti-diabetic medicine known as a sulphonylurea<br />(your doctor may want to reduce your dose of the sulphonylurea when you<br />take it together with Vildus&trade; in order to avoid low blood glucose<br />[hypoglycaemia]).<br />&bull; if you have moderate or severe kidney disease (you will need to take a<br />lower dose of Vildus&trade;).<br />&bull; if you are on dialysis.<br />&bull; if you have liver disease.<br />&bull; if you suffer from heart failure.<br />&bull; if you have or have had a disease of the pancreas.<br />If you have previously taken vildagliptin but had to stop taking it because of<br />liver disease, you should not take this medicine.<br />Diabetic skin lesions are a common complication of diabetes. You are<br />advised to follow the recommendations for skin and foot care that you are<br />given by your doctor or nurse. You are also advised to pay particular<br />attention to new onset of blisters or ulcers while taking Vildus&trade;. Should<br />these occur, you should promptly consult your doctor.<br />A test to determine your liver function will be performed before the start of<br />Vildus&trade; treatment, at three- month intervals for the first year and<br />periodically thereafter. This is so that signs of increased liver enzymes can be<br />detected as early as possible.<br />Children and adolescents<br />The use of Vildus&trade; in children and adolescents up to 18 years of age is not<br />recommended.<br />Other medicines and Vildus&trade;<br />Tell your doctor or pharmacist if you are taking, have recently taken or might<br />take any other medicines.<br />Your doctor may wish to alter your dose of Vildus&trade; if you are taking other<br />medicines such as:<br />- thiazides or other diuretics (also called water tablets)<br />- corticosteroids (generally used to treat inflammation)<br />- thyroid medicines<br />- certain medicines affecting the nervous system.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are<br />planning to have a baby, ask your doctor or pharmacist for advice before<br />taking this medicine.<br />You should not use Vildus&trade; during pregnancy. It is not known if Vildus&trade;<br />passes into breast milk. You should not use Vildus&trade; if you are<br />breast-feeding or plan to breast-feed.<br />Driving and using machines<br />If you feel dizzy while taking Vildus&trade;, do not drive or use machines.<br />Vildus&trade; contains lactose<br />Vildus&trade; contains lactose (milk sugar). If you have been told by your doctor<br />that you have an intolerance to some sugars, contact your doctor before<br />taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with<br />your doctor or pharmacist if you are not sure.<br />How much to take and when<br />The amount of Vildus&trade; people have to take varies depending on their<br />condition. Your doctor will tell you exactly how many tablets of Vildus&trade; to<br />take. The maximum daily dose is 100 mg.<br />The usual dose of Vildus&trade; is either:<br />&bull; 50 mg daily taken as one dose in the morning if you are taking Vildus&trade;<br />with another medicine called a sulphonylurea.<br />&bull; 100 mg daily taken as 50 mg in the morning and 50 mg in the evening if<br />you are taking Vildus&trade; alone, with another medicine called metformin or a<br />glitazone, with a combination of metformin and a sulphonylurea, or with<br />insulin.<br />&bull; 50 mg daily in the morning if you have moderate or severe kidney disease<br />or if you are on dialysis.<br />How to take Vildus&trade;<br />&bull; Swallow the tablets whole with some water.<br />How long to take Vildus&trade;<br />&bull; Take Vildus&trade; every day for as long as your doctor tells you. You may<br />have to take this treatment over a long period of time.<br />&bull; Your doctor will regularly monitor your condition to check that the<br />treatment is having the desired effect.<br />If you take more Vildus&trade; than you should<br />If you take too many Vildus&trade; tablets, or if someone else has taken your<br />medicine, talk to your doctor straight away. Medical attention may be<br />needed. If you need to see a doctor or go to the hospital, take the pack with<br />you.<br />If you forget to take Vildus&trade;<br />If you forget to take a dose of this medicine, take it as soon as you<br />remember. Then take your next dose at the usual time. If it is almost time for<br />your next dose, skip the dose you missed. Do not take a double dose to make<br />up for a forgotten tablet.</p><p>If you stop taking Vildus&trade;<br />Do not stop taking Vildus&trade; unless your doctor tells you to. If you have<br />questions about how long to take this medicine, talk to your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />Some symptoms need immediate medical attention:<br />You should stop taking Vildus&trade; and see your doctor immediately if you<br />experience the following side effects:<br />&bull; Angioedema (rare: may affect up to 1 in 1,000 people): Symptoms<br />include swollen face, tongue or throat, difficulty swallowing, difficulties<br />breathing, sudden onset rash or hives, which may indicate a reaction<br />called &ldquo;angioedema&rdquo;.<br />&bull; Liver disease (hepatitis) (rare): Symptoms include yellow skin and<br />eyes, nausea, loss of appetite or dark-coloured urine, which may indicate<br />liver disease (hepatitis).<br />&bull; Inflammation of the pancreas (pancreatitis) (frequency not known):<br />Symptoms include severe and persistent pain in the abdomen (stomach<br />area), which might reach through to your back, as well as nausea and<br />vomiting.<br />Other side effects<br />Some patients have had the following side effects while taking<br />vildagliptin and metformin:<br />&bull; Common: (may affect up to 1 in 10 people): Trembling, headache,<br />dizziness, nausea, low blood glucose<br />&bull; Uncommon: (may affect up to 1 in 100 people): Tiredness<br />Some patients have had the following side effects while taking<br />vildagliptin and a sulphonylurea:<br />&bull; Common: Trembling, headache, dizziness, weakness, low blood<br />glucose<br />&bull; Uncommon: Constipation<br />&bull; Very rare (may affect up to 1 in 10,000 people): Sore throat,<br />runny nose<br />Some patients have had the following side effects while taking<br />vildagliptin and a glitazone:<br />&bull; Common: Weight increase, swollen hands, ankle or feet (oedema)<br />&bull; Uncommon: Headache, weakness, low blood glucose<br />Some patients have had the following side effects while taking<br />vildagliptin alone:<br />&bull; Common: Dizziness<br />&bull; Uncommon: Headache, constipation, swollen hands, ankle or feet<br />(oedema), joint pain, low blood glucose<br />&bull; Very rare: Sore throat, runny nose, fever<br />Some patients have had the following side effects while taking<br />vildagliptin, metformin and a sulphonylurea:<br />&bull; Common: Dizziness, tremor, weakness, low blood glucose, excessive<br />sweating<br />Some patients have had the following side effects while taking<br />vildagliptin and insulin (with or without metformin):<br />&bull; Common: Headache, chills, nausea (feeling sick), low blood glucose,<br />heartburn<br />&bull; Uncommon: Diarrhoea, flatulence<br />Since vildagliptin has been marketed, the following side effects have<br />also been reported:<br />&bull; Frequency not known (cannot be estimated from the available data):<br />Itchy rash, inflammation of the pancreas, localised peeling of skin or<br />blisters, muscle pain<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse.<br />This includes any possible side effects not listed in this leaflet.<br />By reporting side effects you can help provide more information on the<br />safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use this medicine after the expiry date which is stated on the<br />blister and the carton after &lsquo;EXP&rsquo;.<br />Do not store above 30 &deg;C.<br />Store in the original package in order to protect from moisture.<br />Do not use any Vildus&trade; pack that is damaged or shows signs of<br />tampering.<br />Do not throw away medicines via wastewater or household waste. Ask<br />your pharmacist how to throw away medicines you no longer use. These<br />measures will help protect the environment.<br />Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Vildus&trade; contains<br />&bull; The active substance is vildagliptin.<br />Each Tablet contains 50mg of Vildagliptin.<br />&bull; The other ingredients are Lactose Anhydrous, Microcrystalline<br />cellulose, Sodium starch glycolate and Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Vildus™ looks like and contents of the pack
Vildus™ 50 mg tablets are white to light yellowish, round, flat faced,
beveled edge tablet, debossed with "JP" on one side and "202" on the
other side.
Vildus™ tablet are available in the following packs:
Vildus™ are available in a box of 3 blisters, 10 tablets per each blister.
Vildus™ are available in a box of 6 blisters, 10 tablets per each blister.
Not all pack sizes may be marketed in your country.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,<br />Jeddah, Makkah region, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>على المادة الفعالة فيلداجليبتين والتي تنتمي إلى مجموعة من الأدوية &trade; يحتوي عقار فيلدس<br />تسمى &quot;الأدوية المعالجة لمرض السكر والتي يتم تناولها عن طريق الفم&quot;.<br />لعلاج المرضى من البالغين الذين يعانون من مرض السكري من &trade; يستخدم عقار فيلدس<br />النوع ۲. يتم استخدام هذا العقار في حالة عدم القدرة على التحكم في مرض السكري عن<br />طريق اتباع نظام غذائي وممارسة الرياضة فقط. حيث يساعد على التحكم في مستوي السكر<br />في الدم. إذا لم تحقق الأدوية التي تستخدمها فعالية كافية للتحكم في مرض السكري، سوف<br />إما بمفره أو بمصاحبة أدوية أخرى تتحكم بمستوى &trade; يقوم طبيبك بوصف عقار فيلدس<br />السكر بالدم والتي قد تكون تتناولها بالفعل.<br />يظهر مرض السكري من النوع ۲ في حالة عدم إفراز الجسم كمية كافية من الأنسولين أو إذا<br />كان الأنسولين الذي يفرزه الجسم لا يعمل بالشكل الكافي. يمكن أن يظهر المرض أيضًا إذا<br />كان الجسم يفرز كمية كبيرة من الجلوكاجون.<br />الأنسولين هو المادة التي تساعد على تقليل مستوى السكر في الدم وعلى وجه الخصوص بعد<br />تناول الوجبات. كما أن الجلوكاجون هي المادة التي تحفز الكبد على إنتاج السكر، مما يؤدي<br />إلى ارتفاع مستوى السكر في الدم، ويقوم البنكرياس بإفراز هاتين المادتين.<br />&trade; كيف يعمل عقار فيلدس<br />من خلال تحفيز البنكرياس على إفراز كمية أكبر من الأنسولين وكمية &trade; يعمل عقار فيلدس<br />أقل من الجلوكاجون. يساعد هذا الدواء على التحكم في مستوى السكر في الدم. وقد ثبت أن<br />هذا الدواء يقلل من نسبة السكر في الدم، مما قد يساعد على منع حدوث مضاعفات نتيجة<br />لمرض السكري. وحتى مع البدء بتناول دواء لعلاج مرض السكري، إلا أنه من المهم اتباع<br />نظام غذائي و/ أو ممارسة التمارين الرياضية المحددة لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول عقار فيلدس<br />&bull; إذا كنت تعاني من حساسية تجاه مادة فيلداجليبتين أو أي مكون من المكونات الأخرى<br />الداخلة في تركيب هذا الدواء (المدرجة في القسم رقم ٦). لا تتناول هذا الدواء وتحدث إلى<br />طبيبك، إذا كنت تعتقد أنك تعاني من حساسية تجاه مادة فيلداجليبتين أو أي مكون من<br />.&trade; المكونات الأخرى الداخلة في تركيب عقار فيلدس<br />تحذيرات واحتياطات<br />في &trade; استشر طبيبك أو الصيدلي أو الممرض(ة) المتابع(ة) لحالتك قبل تناول عقار فيلدس<br />الحالات التالية.<br />&bull; إذا كنت تعاني من مرض السكري من النوع ۱ (أي أن جسمك لا يقوم بإفراز الأنسولين) أو<br />إذا كنت تعاني من حالة تسمى حماض كيتوني سكري.<br />&bull; إذا كنت تتناول أية أدوية خافضة للسكر مثل سلفونيليوريا (سيحتاج طبيبك إلى تقليل<br />لتجنب &trade; الجرعة الخاصة بك من عقار سلفونيليوريا عند تناوله بمصاحبة عقار فيلدس<br />انخفاض نسبة الجلوكوز في الدم (نقص سكر الدم).<br />&bull; إذا كنت تعاني من مرض كلوي تتراوح شدته من متوسط إلى حاد (ستحتاج إلي تناول<br />.(&trade; جرعة أقل من عقار فيلدس<br />&bull; إذا كنت تخضع لغسيل كلوي.<br />&bull; إذا كنت تعاني من مرض بالكبد.<br />&bull; إذا كنت تعاني من فشل القلب.<br />&bull; إذا كنت تعاني أو عانيت من مرض بالبنكرياس.<br />يحظر تناول هذا الدواء، إذا كنت قد تناولت فيلداجليبتين في السابق واضطررت للتوقف عن<br />تناوله بسبب مرض بالكبد.<br />تعد الأمراض الجلدية المصاحبة لمرض السكري من المضاعفات الشائعة لمرض السكري.<br />يُوصي باتباع توصيات العناية بالبشرة والقدم التي يقدمها طبيبك أو الممرض(ة) المتابع (ة)<br />لحالتك. كما يُوصي بإيلاء اهتمام خاص للبثور أو التقرحات التي تظهر حديثًا أثناء العلاج<br />يجب استشارة طبيبك فوراً، إذا تعرضت لهذه الأعراض. .&trade; باستخدام عقار فيلدس<br />سيتم إجراء اختبار للتأكد من أن وظائف الكبد تعمل بشكل طبيعي قبل بدء العلاج بعقار<br />ومرة كل ثلاثة أشهر للسنة الأولى وبشكل دوري بعد ذلك. وهذا الإجراء من أجل &trade; فيلدس<br />التمكن من الكشف عن علامات زيادة إنزيمات الكبد بشكل مبكر قدر الإمكان.<br />المرضى من الأطفال والمراهقين<br />في المرضى من الأطفال والمراهقين الذين تصل &trade; لا يُوصي باستخدام عقار فيلدس<br />أعمارهم أو تقل عن ۱۸ سنة.<br />.&trade; تناول أدوية أخري مع عقار فيلدس<br />أبلغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أية أدوية أخري.<br />إذا كنت تتناول أدوية ،&trade; قد يرغب طبيبك في تغيير الجرعة الخاصة بك من عقار فيلدس<br />أخرى مثل ما يلي:<br />- الثيازيدات أو مدرات البول الأخرى (تسمى أيضًا أقراص الماء).<br />- الكورتيكوستيرويدات (أدوية تستخدم عادة لعلاج الالتهاب).<br />- الأدوية المستخدمة لعلاج الغدة الدرقية.<br />- بعض الأدوية التي تؤثر على الجهاز العصبي.<br />الحمل والرضاعة الطبيعية<br />إذا كنتِ حاملًا أو تمارسين الرضاعة الطبيعية أو تعتقدين أنكِ حاملاً أو تخطِّطين للإنجاب،<br />فاستشيري طبيبك أو الصيدلي قبل تناوُل هذا الدَّواء.<br />أثناء الحمل، حيث أنه من غير المعروف ما إذا كان &trade; يحظر عليكِ استخدام عقار فيلدس<br />إذا كنتِ &trade; يفرز في لبن الأم أم لا. يحظر عليكِ استخدام عقار فيلدس &trade; عقار فيلدس<br />تمارسين الرضاعة الطبيعية أو تخططين لممارسة الرضاعة الطبيعة.<br />القيادة واستخدام الآلات<br />فتجنب القيادة أو استخدام الآلات. ،&trade; إذا كنت تشعر بدوخة أثناء العلاج باستخدام فيلدس<br />على اللاكتوز &trade; يحتوي عقار فيلدس<br />على سكر اللاكتوز (سكر اللبن)، لذلك إذا أخبرك طبيبك بأنك لا &trade; يحتوي عقار فيلدس<br />تتحمل بعض أنواع السكريات، فاتصل به قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا هذا الدَّواء تمامًا كما أخبرك طبيبك. قم باستشارة طبيبك أو الصيدلي إذا لم تكن<br />متأكدًا من كيفية التناول.<br />مقدار الجرعات وموعد تناولها<br />التي يجب على المرضى تناولها وفقًا لحالتهم الصحية. سيخبرك &trade; تختلف كمية عقار فيلدس<br />والجرعة القصوى .&trade; طبيبك كم عدد الأقراص التي يجب تناولها تحديدًا من عقار فيلدس<br />اليومية هي ۱۰۰ ملجم.<br />هي إما : &trade; الجرعة المعتادة من عقار فيلدس<br />&trade; &bull; جرعة ٥۰ ملجم مرة واحدة يوميًا، يتم تناولها في الصباح، إذا كنت تتناول عقار فيلدس<br />بمصاحبة دواء اخر يسمي سلفونيليوريا.<br />&bull; جرعة ۱۰۰ ملجم يوميًا، يتم تناول ٥۰ ملجم في الصباح و ٥۰ ملجم في المساء، إذا كنت<br />بمفرده، أو بمصاحبة أدوية اخري تسمي ميتفورمين أو جليتازون، أو &trade; تتناول عقار فيلدس<br />بمصاحبة كل من عقاري ميتفورمين وسلفونيليوريا أو مع الأنسولين.<br />&bull; جرعة ٥۰ ملجم يوميًا، يتم تناولها في الصباح، إذا كنت تعاني من مرض كلوي معتدل أو<br />حاد أو إذا كنت تخضع للغسيل الكلوي.<br />&trade; كيفية تناول عقار فيلدس<br />&bull; ابتلع القرص كاملًا مع بعض الماء.<br />؟&trade; مدة تناول عقار فيلدس<br />كل يوم وفقًا لتعليمات طبيبك. قد تحتاج إلى تناول هذا العلاج لفترة &trade; &bull; تناوُل عقار فيلدس<br />طويلة من الوقت.<br />&bull; سيُراقب طبيبك حالتك دوريًا للتحقق مما إذا كان العلاج يُعطي التأثير المطلوب أم لا.<br />؟&trade; إذا تناولت جرعة أكبر مما يجب تناولها من عقار فيلدس<br />أو إذا قام شخص آخر بتناول الدواء &trade; إذا تناولت كمية كبيرة جدًا من أقراص عقار فيلدس<br />الخاص بك، فتحدث إلى طبيبك فورًا. قد يتطلب هذا الأمر رعاية طبية. احضر عبوة الدواء<br />معك، إذا كنت بحاجة إلى زيارة طبيبك أو الذهاب إلى المستشفى.<br />&trade; إذا أغفلت تناوُل عقار فيلدس<br />إذا أغفلت تناول جرعة من هذا الدواء، فتناولها بمجرد تذكرك لها. ثم تناول الجرعة التَّالية في<br />الوقت المُعتاد. ومع ذلك، إذا حان موعد الجُرعة التَّالية، فتجاوَز الجُرعة التي أغفلتها، ولا<br />تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.<br />&trade; إذا توقفت عن تناول عقار فيلدس<br />ما لم يخبرك طبيبك بذلك. تحدث إلي طبيبك، إذا كانت ،&trade; لا تتوقف عن تناول عقار فيلدس<br />.&trade; لديك أية أسئلة عن مدة العلاج بعقار فيلد</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد يُسبب هذا الدواء، مثله مثل كافة الأدوية، آثارًا جانبية على الرغم من عدم حدوثها لجميع<br />المرضى.<br />تحتاج بعض الأعراض إلي عناية طبية عاجلة:<br />والذهاب إلى طبيبك على الفور إذا عانيت من أي &trade; يجب التوقف عن تناول عقار فيلدس<br />من الآثار الجانبية التالية:<br />&bull; وذمة وعائية (آثار جانبية نادرة: قد تُؤثر على ما يصل إلى مريض واحد من بين كل<br />۱۰۰۰ مريض): الأعراض تشمل تورم الوجه أو اللسان أو الحلق، صعوبة في البلع،<br />صعوبات في التنفس، ظهور طفح جلدي مفاجئ أو شري، مما قد يشير إلى تفاعلات تسمى<br />&quot;الوذمة الوعائية&quot;.<br />&bull; مرض بالكبد (التهاب الكبد) (آثار جانبية نادرة): الأعراض تشمل اصفرار الجلد والعينين،<br />غثيان، فقدان الشهية أو بول داكن، مما قد يشير إلى مرض بالكبد (التهاب الكبد).<br />&bull; التهاب البنكرياس (آثار جانبية غير معروف معدل تكرارها): تتضمن الأعراض الآم<br />شديدة ودائمة في البطن (منطقة المعدة) قد تصل إلى الظهر مصحوبة بغثيان وقيء.<br />أثار جانبية أخرى<br />تعرض بعض المرضى للآثار الجانبية التالية أثناء تناول فيلداجليبتين و ميتفورمين:<br />&bull; آثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰ مرضى):<br />رعشة، صداع، دوخة، غثيان، انخفاض نسبة الجلوكوز في الدم.<br />&bull; آثار جانبية غير شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰۰<br />مريض): شعور بالإرهاق.<br />تعرض بعض المرضى للأثار الجانبية التالية أثناء تناول فيلداجليبتين مع سلفونيليوريا:<br />&bull; آثار جانبية شائعة: رعشة، صداع، دوخة، ضعف، انخفاض نسبة الجلوكوز في الدم.<br />&bull; آثار جانبية غير شائعة: إمساك.<br />&bull; آثار جانبية نادرة جدًا (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰٫۰۰۰<br />مريض): قرح بالحلق، سيلان الأنف.<br />تعرض بعض المرضى للأثار الجانبية التالية أثناء تناول فيلداجليبتين مع جليتازون:<br />&bull; آثار جانبية شائعة: زيادة الوزن، تورم اليدين أو الكاحل أو القدمين (وذمة)<br />&bull; آثار جانبية غير شائعة: صداع، ضعف، انخفاض مستوى الجلوكوز في الدم.<br />تعرض بعض المرضى للآثار الجانبية التالية أثناء تناول فيلداجليبتين بمفرده:<br />&bull; آثار جانبية شائعة: دوخة<br />&bull; آثار جانبية غير شائعة: صداع، إمساك، تورم اليدين أو الكاحل أو القدمين (وذمة)، ألم<br />بالمفاصل، انخفاض نسبة الجلوكوز في الدم<br />&bull; آثار جانبية نادرة جدًا: قرح بالحلق، سيلان الأنف، حمى.<br />تعرض بعض المرضى للأثار الجانبية التالية أثناء تناول فيلداجليبتين مع ميتفورمين<br />وسلفونيليوريا:<br />&bull; آثار جانبية شائعة: دوخة، رعشة، ضعف، انخفاض نسبة الجلوكوز في الدم، فرط إفراز<br />العرق.<br />تعرض بعض المرضى للآثار الجانبية التالية أثناء تناول فيلداجليبتين مع الأنسولين (مع أو<br />بدون ميتفورمين):<br />&bull; آثار جانبية شائعة: صداع، قشعريرة، غثيان (شعور بإعياء)، انخفاض نسبة الجلوكوز في<br />الدم، حرقة المعدة (حموضة).<br />&bull; آثار جانبية غير شائعة: إسهال، انتفاخ البطن.<br />تم الإبلاغ أيضًا عن الآثار الجانبية التالية منذ بداية تسويق فيلداجليبتين:<br />&bull; آثار جانبية غير معروف معدل تكرارها (لا يمكن تقديرها من واقع البيانات المتاحة):<br />طفح جلدي مصحوب بحكة، التهاب البنكرياس، تقشر موضعي للجلد أو ظهور بثور، ألم في<br />العضلات.<br />الإبلاغ عن الآثار الجانبية<br />إذا شعرت بأية آثار جانبية، استشر طبيبك أو الصيدلي أو الممرض(ة) المتابع(ة) لحالتك.<br />يشمل ذلك أية آثار جانبية مُحتمَلة، غير مُدرجة في هذه النَّشرة. يمكنك المساعدة في توفير<br />معلومات إضافية حول أمان استخدام هذا الدَّواء من خلال إبلاغك عن الآثار الجانبية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ بعيدًا عن متناول و مرأى الأطفال.<br />لا تتناول هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدوّن على العبوة الكرتونية والشريط بعد كلمة<br />.&quot;EXP&quot;<br />يُحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />يُحفظ في العبوة الأصلية للحماية من الرطوبة.<br />أو تظهر عليها علامات عبث. &trade; لا تستخدم أي عبوة تالفة من عقار فيلدس<br />لاتقمْ بالتخلّص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلّفات المنزلية. استشر<br />الصيدلي الخاص بك حول كيفية التَّخلص من الأدوية التي لم تعد تحتاج إليها. حيث تُساعد هذه<br />التدابير في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><br />&trade; &bull; يحتوي عقار فيلدس على المادة الفعالة فيلداجليبتين.<br />يحتوي كل قرص على ٥۰ ملجم من فيلداجليبتين<br />&bull; المكونات الأخرى هي لاكتوز لا مائي، سليلوز دقيق التبلور، جليكولات نشا الصوديوم، و<br />ستيرات الماغنسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>٥۰ ملجم أقراص لونها أبيض يميل إلى أصفر فاتح، دائرية الشكل، ذات &trade; عقار فيلدس<br />و &quot; 202 &quot; على الجانب الآخر. &quot;JP&quot; وجه مسطح، محفور على أحد جانبيها<br />في علبة تحتوي على ۳ شرائط في كل شريط ۱۰ أقراص. &trade; تتوفر أقراص فيلدس<br />في علبة تحتوي على ٦ شرائط في كل شريط ۱۰ أقراص. &trade; تتوفر أقراص فيلدس<br />قد لا تكون جميع العبوات مسوقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>شركة مصنع جمجوم للأدوية،</p><p>جدة، المملكة العربية السعودية.</p><p>&nbsp;هاتف: 6081111-12-966+</p><p>&nbsp;فاكس: 6081222-12-966+</p><p>الموقع الإلكتروني www.jamjoompharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vildus 50mg Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 50 mg of Vildagliptin.
Excipient with known effect: Each tablet contains 47.82 mg lactose (anhydrous).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White to light yellowish, round, flat faced, beveled edge tablet, debossed with "JP" on one side and
"202" on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults:<br />As monotherapy<br />- In patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate<br />due to contraindications or intolerance.<br />As dual oral therapy in combination with<br />- Metformin, in patients with insufficient glycaemic control despite maximal tolerated dose of<br />monotherapy with metformin,<br />- A sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a<br />sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance,<br />- A thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a<br />thiazolidinedione is appropriate.<br />As triple oral therapy in combination with<br />- A sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal<br />products do not provide adequate glycaemic control.<br />Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet<br />and exercise plus a stable dose of insulin do not provide adequate glycaemic control.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adults<br />When used as monotherapy, in combination with metformin, in combination with thiazolidinedione, in<br />combination with metformin and a sulphonylurea, or in combination with insulin (with or without<br />metformin), the recommended daily dose of Vildagliptin is 100 mg, administered as one dose of 50 mg<br />in the morning and one dose of 50 mg in the evening.</p><p>When used in dual combination with a sulphonylurea, the recommended dose of Vildagliptin is 50 mg<br />once daily administered in the morning. In this patient population, Vildagliptin 100 mg daily was no<br />more effective than Vildagliptin 50 mg once daily.<br />When used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be considered<br />to reduce the risk of hypoglycaemia.<br />Doses higher than 100 mg are not recommended.<br />If a dose of Vildagliptin is missed, it should be taken as soon as the patient remembers. A double dose<br />should not be taken on the same day.<br />The safety and efficacy of Vildagliptin as triple oral therapy in combination with metformin and a<br />thiazolidinedione have not been established.<br />Additional information on special populations<br />Elderly (&ge; 65 years)<br />No dose adjustments are necessary in elderly patients (see also sections 5.1 and 5.2).<br />Renal impairment<br />No dose adjustment is required in patients with mild renal impairment (creatinine clearance &ge; 50<br />ml/min). In patients with moderate or severe renal impairment or with end-stage renal disease (ESRD),<br />the recommended dose of Vildagliptin is 50 mg once daily (see also sections 4.4, 5.1 and 5.2).<br />Hepatic impairment<br />Vildagliptin should not be used in patients with hepatic impairment, including patients with pretreatment<br />alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3x the upper limit of<br />normal (ULN) (see also sections 4.4 and 5.2).<br />Paediatric population<br />Vildagliptin is not recommended for use in children and adolescents (&lt; 18 years). The safety and<br />efficacy of Vildagliptin in children and adolescents (&lt; 18 years) have not been established. No data are<br />available (see also section 5.1).<br />Method of administration<br />Oral use<br />Vildagliptin can be administered with or without a meal (see also section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General<br />Vildagliptin is not a substitute for insulin in insulin-requiring patients. Vildagliptin should not be used in<br />patients with type 1 diabetes or for the treatment of diabetic ketoacidosis</p><p>Renal impairment<br />There is limited experience in patients with ESRD on haemodialysis. Therefore Vildagliptin should be<br />used with caution in these patients (see also sections 4.2, 5.1 and 5.2).<br />Hepatic impairment<br />Vildagliptin should not be used in patients with hepatic impairment, including patients with pretreatment<br />ALT or AST &gt; 3x ULN (see also sections 4.2 and 5.2).<br />Liver enzyme monitoring<br />Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients<br />were generally asymptomatic without clinical sequelae and liver function test results returned to normal<br />after discontinuation of treatment. Liver function tests should be performed prior to the initiation of<br />treatment with Vildagliptin in order to know the patient&#39;s baseline value. Liver function should be<br />monitored during treatment with Vildagliptin at three-month intervals during the first year and<br />periodically thereafter. Patients who develop increased transaminase levels should be monitored with a<br />second liver function evaluation to confirm the finding and be followed thereafter with frequent liver<br />function tests until the abnormality(ies) return(s) to normal. Should an increase in AST or ALT of 3x<br />ULN or greater persist, withdrawal of Vildagliptin therapy is recommended.<br />Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue<br />Vildagliptin.<br />Following withdrawal of treatment with Vildagliptin and LFT normalisation, treatment with Vildagliptin<br />should not be reinitiated.<br />Cardiac failure<br />A clinical trial of Vildagliptin in patients with New York Heart Association (NYHA) functional class IIII<br />showed that treatment with Vildagliptin was not associated with a change in left-ventricular function<br />or worsening of pre-existing congestive heart failure (CHF) versus placebo. Clinical experience in<br />patients with NYHA functional class III treated with Vildagliptin is still limited and results are<br />inconclusive (see section 5.1).<br />There is no experience of Vildagliptin use in clinical trials in patients with NYHA functional class IV<br />and therefore use is not recommended in these patients.</p><p>Skin disorders<br />Skin lesions, including blistering and ulceration have been reported in extremities of monkeys in nonclinical<br />toxicology studies (see section 5.3). Although skin lesions were not observed at an increased<br />incidence in clinical trials, there was limited experience in patients with diabetic skin complications.<br />Furthermore, there have been post-marketing reports of bullous and exfoliative skin lesions. Therefore,<br />in keeping with routine care of the diabetic patient, monitoring for skin disorders, such as blistering or<br />ulceration, is recommended.<br />Acute pancreatitis<br />Use of Vildagliptin has been associated with a risk of developing acute pancreatitis. Patients should be<br />informed of the characteristic symptom of acute pancreatitis.<br />If pancreatitis is suspected, Vildagliptin should be discontinued; if acute pancreatitis is confirmed,<br />Vildagliptin should not be restarted. Caution should be exercised in patients with a history of acute<br />pancreatitis.</p><p>Hypoglycaemia<br />Sulphonylureas are known to cause hypoglycaemia. Patients receiving Vildagliptin in combination with<br />a sulphonylurea may be at risk for hypoglycaemia. Therefore, a lower dose of sulphonylurea may be<br />considered to reduce the risk of hypoglycaemia.<br />Excipients<br />The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp<br />lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>4.5 Interaction with other medicinal products and other forms of interaction<br />Vildagliptin has a low potential for interactions with co-administered medicinal products. Since<br />Vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP 450<br />enzymes, it is not likely to interact with active substances that are substrates, inhibitors or inducers of<br />these enzymes.<br />Combination with pioglitazone, metformin and glyburide<br />Results from studies conducted with these oral antidiabetics have shown no clinically relevant<br />pharmacokinetic interactions.<br />Digoxin (Pgp substrate), warfarin (CYP2C9 substrate)<br />Clinical studies performed with healthy subjects have shown no clinically relevant pharmacokinetic<br />interactions. However, this has not been established in the target population.<br />Combination with amlodipine, ramipril, valsartan or simvastatin<br />Drug-drug interaction studies in healthy subjects were conducted with amlodipine, ramipril, valsartan<br />and simvastatin. In these studies, no clinically relevant pharmacokinetic interactions were observed after<br />co-administration with Vildagliptin.<br />Combination with ACE-inhibitors<br />There may be an increased risk of angioedema in patients concomitantly taking ACE-inhibitors.(see<br />section 4.8).<br />As with other oral antidiabetic medicinal products the hypoglycaemic effect of Vildagliptin may be<br />reduced by certain active substances, including thiazides, corticosteroids, thyroid products and<br />sympathomimetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no adequate data from the use of Vildagliptin in pregnant women. Studies in animals have<br />shown reproductive toxicity at high doses (see section 5.3). The potential risk for humans is unknown.<br />Due to lack of human data, Vildagliptin should not be used during pregnancy.<br />Breast-feeding<br />It is unknown whether Vildagliptin is excreted in human milk. Animal studies have shown excretion of<br />Vildagliptin in milk. Vildagliptin should not be used during breast-feeding.<br />Fertility<br />No studies on the effect on human fertility have been conducted for Vildagliptin (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Patients who<br />experience dizziness as an adverse reaction should avoid driving vehicles or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Safety data were obtained from a total of 3,784 patients exposed to Vildagliptin at a daily dose of 50 mg<br />(once daily) or 100 mg (50 mg twice daily or 100 mg once daily) in controlled trials of at least 12 weeks<br />duration. Of these patients, 2,264 patients received Vildagliptin as monotherapy and 1,520 patients<br />received Vildagliptin in combination with another medicinal product. 2,682 patients were treated with<br />Vildagliptin 100 mg daily (either 50 mg twice daily or 100 mg once daily) and 1,102 patients were<br />treated with Vildagliptin 50 mg once daily.<br />The majority of adverse reactions in these trials were mild and transient, not requiring treatment<br />discontinuations. No association was found between adverse reactions and age, ethnicity, duration of<br />exposure or daily dose.<br />Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients<br />were generally asymptomatic without clinical sequelae and liver function returned to normal after<br />discontinuation of treatment. In data from controlled monotherapy and add-on therapy trials of up to 24<br />weeks in duration, the incidence of ALT or AST elevations &ge; 3x ULN (classified as present on at least 2<br />consecutive measurements or at the final on-treatment visit) was 0.2%, 0.3% and 0.2% for Vildagliptin<br />50 mg once daily, Vildagliptin 50 mg twice daily and all comparators, respectively. These elevations in<br />transaminases were generally asymptomatic, non-progressive in nature and not associated with<br />cholestasis or jaundice.<br />Rare cases of angioedema have been reported on Vildagliptin at a similar rate to controls. A greater<br />proportion of cases were reported when Vildagliptin was administered in combination with an<br />angiotensin converting enzyme inhibitor (ACE-Inhibitor). The majority of events were mild in severity<br />and resolved with ongoing Vildagliptin treatment.<br />Tabulated list of adverse reactions<br />Adverse reactions reported in patients who received Vildagliptin in double-blind studies as monotherapy<br />and add-on therapies are listed below for each indication by system organ class and absolute frequency.<br />Frequencies are defined as very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to<br />&lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the<br />available data). Within each frequency grouping, adverse reactions are presented in order of decreasing<br />seriousness.<br />Combination with metformin</p><p>Table 1 Adverse reactions reported in patients who received Vildagliptin 100 mg daily in combination with metformin in double-blind studies (N=208)</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.85pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt; margin-right:0in">Hypoglycaemia</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Tremor</p></td></tr><tr><td style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.85pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Headache</p></td></tr></tbody></table><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt; margin-right:0in">Dizziness</p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Uncommon</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Fatigue</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.85pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Nausea</p></td></tr></tbody></table><p style="margin-left:19.55pt; text-align:justify"><em>Description of selected adverse reactions</em></p><p style="margin-left:19.55pt; margin-right:18.6pt; text-align:justify">In controlled clinical trials with the combination of Vildagliptin 100 mg daily + metformin, no withdrawal due to adverse reactions was reported in either the Vildagliptin 100 mg daily + metformin or the placebo + metformin treatment groups.</p><p style="margin-left:19.55pt; margin-right:18.7pt; text-align:justify">In clinical trials, the incidence of hypoglycaemia was common in patients receiving Vildagliptin 100 mg daily in combination with metformin (1%) and uncommon in patients receiving placebo + metformin (0.4%). No severe hypoglycaemic events were reported in the Vildagliptin arms.</p><p style="margin-right:18.8pt; text-align:justify">In clinical trials, weight did not change from baseline when Vildagliptin 100 mg daily was added to metformin (+0.2 kg and -1.0 kg for Vildagliptin and placebo, respectively).</p><p style="margin-left:19.55pt; margin-right:19.2pt; text-align:justify">Clinical trials of up to more than 2 years&#39; duration did not show any additional safety signals or unforeseen risks when Vildagliptin was added on to metformin.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:19.55pt; text-align:justify"><em><u>Combination with a sulphonylurea</u></em></p><p>Table 2 Adverse reactions reported in patients who received Vildagliptin 50 mg in combination with a sulphonylurea in double-blind studies (N=170)</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Very rare</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Nasopharyngitis</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:7.2in"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt; margin-right:0in">Hypoglycaemia</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Tremor</p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Headache</p></td></tr><tr><td style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.85pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Dizziness</p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt; margin-right:0in">Asthenia</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.9pt; vertical-align:top; width:103.7pt"><p>Uncommon</p></td><td style="height:16.9pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Constipation</p></td></tr></tbody></table><p style="margin-left:19.55pt; text-align:justify"><em>Description of selected adverse reactions</em></p><p style="margin-left:19.55pt; margin-right:18.8pt; text-align:justify">In controlled clinical trials with the combination of Vildagliptin 50 mg + a sulphonylurea, the overall incidence of withdrawals due to adverse reactions was 0.6% in the Vildagliptin 50 mg + sulphonylurea vs 0% in the placebo + sulphonylurea treatment group.</p><p style="margin-right:18.8pt; text-align:justify">In clinical trials, the incidence of hypoglycaemia when Vildagliptin 50 mg once daily was added to glimepiride was 1.2% versus 0.6% for placebo + glimepiride. No severe hypoglycaemic events were reported in the Vildagliptin arms.</p><p style="margin-left:19.55pt; margin-right:18.75pt; text-align:justify">In clinical trials, weight did not change from baseline when Vildagliptin 50 mg daily was added to glimepiride (-0.1 kg and -0.4 kg for Vildagliptin and placebo, respectively).</p><p style="margin-left:19.55pt; margin-right:0in; text-align:justify"><em><u>Combination with a thiazolidinedione</u></em></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;</em></p><p>Table 3 Adverse reactions reported in patients who received Vildagliptin 100 mg daily in combination with a thiazolidinedione in double-blind studies (N=158)</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.85pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Weight increase</p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Uncommon</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt; margin-right:0in">Hypoglycaemia</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Uncommon</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Headache</p></td></tr><tr><td style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:103.7pt"><p>Uncommon</p></td><td style="height:16.85pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Asthenia</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Oedema peripheral</p></td></tr></tbody></table><p style="margin-left:19.55pt; text-align:justify"><em>Description of selected adverse reactions</em></p><p style="margin-right:18.9pt; text-align:justify">In controlled clinical trials with the combination of Vildagliptin 100 mg daily+ a thiazolidinedione, no withdrawal due to adverse reactions was reported in either the Vildagliptin 100 mg daily + thiazolidinedione or the placebo + thiazolidinedione treatment groups.</p><p style="margin-right:18.6pt; text-align:justify">In clinical trials, the incidence of hypoglycaemia was uncommon in patients receiving Vildagliptin + pioglitazone (0.6%) but common in patients receiving placebo + pioglitazone (1.9%). No severe hypoglycaemic events were reported in the Vildagliptin arms.</p><p style="margin-left:19.55pt; margin-right:18.6pt; text-align:justify">In the pioglitazone add-on study, the absolute weight increases with placebo, Vildagliptin 100 mg daily were 1.4 and 2.7 kg, respectively.</p><p style="margin-left:19.55pt; margin-right:18.85pt; text-align:justify">The incidence of peripheral oedema when Vildagliptin 100 mg daily was added to a maximum dose of background pioglitazone (45 mg once daily) was 7.0%, compared to 2.5% for background pioglitazone alone.</p><p style="margin-left:19.55pt; margin-right:0in"><em><u>Monotherapy</u></em></p><p>Table 4 Adverse reactions reported in patients who received Vildagliptin 100 mg daily as monotherapy in double-blind studies (N=1,855)</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td colspan="2" style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:7.2in"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Very rare</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt; margin-right:0in">Upper respiratory tract infection</p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Very rare</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Nasopharyngitis</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.9pt; vertical-align:top; width:103.7pt"><p>Uncommon</p></td><td style="height:16.9pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Hypoglycaemia</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Dizziness</p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Uncommon</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Headache</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:103.7pt"><p>Uncommon</p></td><td style="height:16.85pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Oedema peripheral</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Uncommon</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Constipation</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:103.7pt"><p>Uncommon</p></td><td style="height:16.85pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Arthralgia</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-left:19.55pt; margin-right:0in; text-align:justify"><em>Description of selected adverse reactions</em></p><p style="margin-left:19.55pt; margin-right:18.75pt; text-align:justify">In addition, in controlled monotherapy trials with Vildagliptin the overall incidence of withdrawals due to adverse reactions was no greater for patients treated with Vildagliptin at doses of 100 mg daily (0.3%) than for placebo (0.6%) or comparators (0.5%).</p><p style="margin-right:18.8pt; text-align:justify">In comparative controlled monotherapy studies, hypoglycaemia was uncommon, reported in 0.4% (7 of 1,855) of patients treated with Vildagliptin 100 mg daily compared to 0.2% (2 of 1,082) of patients in the groups treated with an active comparator or placebo, with no serious or severe events reported.</p><p style="margin-left:19.55pt; margin-right:18.8pt; text-align:justify">In clinical trials, weight did not change from baseline when Vildagliptin 100 mg daily was administered as monotherapy (-0.3 kg and -1.3 kg for Vildagliptin and placebo, respectively).</p><p style="margin-left:19.55pt; margin-right:18.8pt; text-align:justify">Clinical trials of up to 2 years&#39; duration did not show any additional safety signals or unforeseen risks with Vildagliptin monotherapy.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:19.55pt; margin-right:0in; text-align:justify"><em><u>Combination with metformin and a sulphonylurea</u></em></p><p>Table 5 Adverse reactions reported in patients who received Vildagliptin 50 mg twice daily in combination with metformin and a sulphonylurea (N=157)</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Metabolism and nutritional disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.85pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Hypoglycaemia</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Dizziness, tremor</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.85pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Hyperhidrosis</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Asthenia</p></td></tr></tbody></table><p style="margin-left:19.55pt; text-align:justify"><em>Description of selected adverse reactions</em></p><p style="margin-right:18.65pt; text-align:justify">There were no withdrawals due to adverse reactions reported in the Vildagliptin + metformin + glimepiride treatment group versus 0.6% in the placebo + metformin + glimepiride treatment group.</p><p style="margin-left:19.55pt; margin-right:18.6pt; text-align:justify">The incidence of hypoglycaemia was common in both treatment groups (5.1% for the Vildagliptin + metformin + glimepiride group versus 1.9% for the placebo + metformin + glimepiride group). One severe hypoglycaemic event was reported in the Vildagliptin group.</p><p style="text-align:justify">At the end of the study, effect on mean body weight was neutral (+0.6 kg in the Vildagliptin group and -</p><p>0.1 kg in the placebo group).</p><p style="margin-left:19.55pt; margin-right:0in; text-align:justify"><em><u>Combination with insulin</u></em></p><p>Table 6 Adverse reactions reported in patients who received Vildagliptin 100 mg daily in combination with insulin (with or without metformin) in double-blind studies (N=371)</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Decreased blood glucose</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="height:16.85pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Headache, chills</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Gastrointestinal disorders</strong></p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Common</p></td><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt; margin-right:0in">Nausea, gastro-oesophageal reflux disease</p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Uncommon</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Diarrhoea, flatulence</p></td></tr></tbody></table><p style="margin-left:19.55pt"><em>Description of selected adverse reactions</em></p><p style="margin-right:18.7pt; text-align:justify">In controlled clinical trials using Vildagliptin 50 mg twice daily in combination with insulin, with or without concomitant metformin, the overall incidence of withdrawals due to adverse reactions was 0.3% in the Vildagliptin treatment group and there were no withdrawals in the placebo group.</p><p style="margin-right:18.6pt; text-align:justify">The incidence of hypoglycaemia was similar in both treatment groups (14.0% in the Vildagliptin group vs 16.4% in the placebo group). Two patients reported severe hypoglycaemic events in the Vildagliptin group, and 6 patients in the placebo group.</p><p style="margin-left:19.55pt; margin-right:19.15pt; text-align:justify">At the end of the study, effect on mean body weight was neutral (+0.6 kg change from baseline in the Vildagliptin group and no weight change in the placebo group).</p><p style="margin-left:19.55pt; margin-right:0in; text-align:justify"><em><u>Post-marketing experience</u></em></p><p>Table 7 Post-marketing adverse reactions</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Not known</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Pancreatitis</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:44.5pt; vertical-align:top; width:103.7pt"><p>Not known</p></td><td style="height:44.5pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Hepatitis (reversible upon discontinuation of the medicinal product)</p><p style="margin-left:1.4pt; margin-right:0in">Abnormal liver function tests (reversible upon discontinuation of the medicinal product)</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:103.7pt"><p>Not known</p></td><td style="height:16.75pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Myalgia</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:7.2in"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:30.65pt; vertical-align:top; width:103.7pt"><p>Not known</p></td><td style="height:30.65pt; vertical-align:top; width:414.7pt"><p style="margin-left:1.4pt">Urticaria</p><p style="margin-left:1.4pt; margin-right:0in">Exfoliative and bullous skin lesions, including bullous pemphigoid</p></td></tr></tbody></table><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p>&nbsp;<p>&nbsp;</p></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:19.55pt; margin-right:233.65pt; text-align:justify">Information regarding overdose with Vildagliptin is limited. <u>Symptoms</u></p><p style="margin-left:19.55pt; margin-right:18.75pt; text-align:justify">Information on the likely symptoms of overdose was taken from a rising dose tolerability study in healthy subjects given Vildagliptin for 10 days. At 400 mg, there were three cases of muscle pain, and individual cases of mild and transient paraesthesia, fever, oedema and a transient increase in lipase levels. At 600 mg, one subject experienced oedema of the feet and hands, and increases in creatine phosphokinase (CPK), aspartate aminotransferase (AST), C-reactive protein (CRP) and myoglobin levels. Three other subjects experienced oedema of the feet, with paraesthesia in two cases. All symptoms and laboratory abnormalities resolved without treatment after discontinuation of the study medicinal product.</p><p><u>Management</u></p><p style="margin-left:19.55pt; margin-right:18.8pt; text-align:justify">In the event of an overdose, supportive management is recommended. Vildagliptin cannot be removed by haemodialysis. However, the major hydrolysis metabolite (LAY 151) can be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:19.55pt; margin-right:18.9pt">Pharmacotherapeutic group: Drugs used in diabetes, dipeptidyl peptidase 4 (DPP-4) inhibitors, ATC code: A10BH02</p><p style="margin-right:81.05pt">Vildagliptin, a member of the islet enhancer class, is a potent and selective DPP-4 inhibitor. <u>Mechanism of action</u></p><p style="margin-left:19.55pt; margin-right:18.6pt; text-align:justify">The administration of Vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).</p><p><u>Pharmacodynamics effects</u></p><p style="margin-left:19.55pt; margin-right:18.7pt; text-align:justify">By increasing the endogenous levels of these incretin hormones, Vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion. Treatment with Vildagliptin 50-100 mg daily in patients with type 2 diabetes significantly improved markers of beta cell function including HOMA-&beta; (Homeostasis Model Assessment&ndash;&beta;), proinsulin to insulin ratio and measures of beta cell responsiveness from the frequently-sampled meal tolerance test. In non-diabetic (normal glycaemic) individuals, Vildagliptin does not stimulate insulin secretion or reduce glucose levels.</p><p style="margin-right:18.9pt">By increasing endogenous GLP-1 levels, Vildagliptin also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion.</p><p style="margin-left:19.55pt; margin-right:18.95pt; text-align:justify">The enhanced increase in the insulin/glucagon ratio during hyperglycaemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.</p><p>The known effect of increased GLP-1 levels delaying gastric emptying is not observed with Vildagliptin treatment.</p><p style="text-align:justify"><u>Clinical efficacy and safety</u></p><p style="margin-left:19.55pt; margin-right:18.55pt; text-align:justify">More than 15,000 patients with type 2 diabetes participated in double-blind placebo- or active-controlled clinical trials of up to more than 2 years&#39; treatment duration. In these studies, Vildagliptin was administered to more than 9,000 patients at daily doses of 50 mg once daily, 50 mg twice daily or 100 mg once daily. More than 5,000 male and more than 4,000 female patients received Vildagliptin 50 mg once daily or 100 mg daily. More than 1,900 patients receiving Vildagliptin 50 mg once daily or 100 mg daily were &ge; 65 years. In these trials, Vildagliptin was administered as monotherapy in drug-na&iuml;ve patients with type 2 diabetes or in combination in patients not adequately controlled by other&nbsp; antidiabetic medicinal products.</p><p style="margin-right:18.8pt; text-align:justify">Overall, Vildagliptin improved glycaemic control when given as monotherapy or when used in combination with metformin, a sulphonylurea, and a thiazolidinedione, as measured by clinically relevant reductions in HbA1c from baseline at study endpoint (see Table 8).</p><p style="margin-left:19.55pt; margin-right:18.85pt; text-align:justify">In clinical trials, the magnitude of HbA1c reductions with Vildagliptin was greater in patients with higher baseline HbA1c.</p><p style="margin-left:19.55pt; margin-right:18.6pt; text-align:justify">In a 52-week double-blind controlled trial, Vildagliptin (50 mg twice daily) reduced baseline HbA1c by - 1% compared to -1.6% for metformin (titrated to 2 g/day) statistical non-inferiority was not achieved. Patients treated with Vildagliptin reported significantly lower incidences of gastrointestinal adverse reactions versus those treated with metformin.</p><p style="margin-left:19.55pt; margin-right:18.5pt; text-align:justify">In a 24-week double-blind controlled trial, Vildagliptin (50 mg twice daily) was compared to rosiglitazone (8 mg once daily). Mean reductions were -1.20% with Vildagliptin and -1.48% with rosiglitazone in patients with mean baseline HbA1c of 8.7%. Patients receiving rosiglitazone experienced a mean increase in weight (+1.6 kg) while those receiving Vildagliptin experienced no weight gain (-0.3 kg). The incidence of peripheral oedema was lower in the Vildagliptin group than in the rosiglitazone group (2.1% vs. 4.1% respectively).</p><p style="margin-right:18.6pt; text-align:justify">In a clinical trial of 2 years&#39; duration, Vildagliptin (50 mg twice daily) was compared to gliclazide (up to 320 mg/day). After two years, mean reduction in HbA1c was -0.5% for Vildagliptin and -0.6% for gliclazide, from a mean baseline HBA1c of 8.6%. Statistical non-inferiority was not achieved. Vildagliptin was associated with fewer hypoglycaemic events (0.7%) than gliclazide (1.7%).</p><p style="margin-left:19.55pt; margin-right:18.7pt; text-align:justify">In a 24-week trial, Vildagliptin (50 mg twice daily) was compared to pioglitazone (30 mg once daily) in patients inadequately controlled with metformin (mean daily dose: 2020 mg). Mean reductions from baseline HbA1c of 8.4% were -0.9% with Vildagliptin added to metformin and -1.0% with pioglitazone added to metformin. A mean weight gain of +1.9 kg was observed in patients receiving pioglitazone added to metformin compared to +0.3 kg in those receiving Vildagliptin added to metformin.</p><p style="margin-left:19.55pt; margin-right:18.55pt; text-align:justify">In a clinical trial of 2 years&#39; duration, Vildagliptin (50 mg twice daily) was compared to glimepiride (up to 6 mg/day &ndash; mean dose at 2 years: 4.6 mg) in patients treated with metformin (mean daily dose: 1894 mg). After 1 year mean reductions in HbA1c were -0.4% with Vildagliptin added to metformin and - 0.5% with glimepiride added to metformin, from a mean baseline HbA1c of 7.3%. Body weight change with Vildagliptin was -0.2 kg vs +1.6 kg with glimepiride. The incidence of hypoglycaemia was significantly lower in the Vildagliptin group (1.7%) than in the glimepiride group (16.2%). At study endpoint (2 years), the HbA1c was similar to baseline values in both treatment groups and the body weight changes and hypoglycaemia differences were maintained.</p><p style="margin-left:19.55pt; margin-right:18.6pt; text-align:justify">In a 52-week trial, Vildagliptin (50 mg twice daily) was compared to gliclazide (mean daily dose: 229.5 mg) in patients inadequately controlled with metformin (metformin dose at baseline 1928 mg/day). After 1 year, mean reductions in HbA1c were -0.81% with Vildagliptin added to metformin (mean baseline HbA1c 8.4%) and -0.85% with gliclazide added to metformin (mean baseline HbA1c 8.5%); statistical</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:19.55pt; margin-right:18.55pt; text-align:justify">non-inferiority was achieved (95% CI -0.11 &ndash; 0.20). Body weight change with Vildagliptin was +0.1 kg compared to a weight gain of +1.4 kg with gliclazide.</p><p style="margin-left:19.55pt; margin-right:18.45pt; text-align:justify">In a 24-week trial the efficacy of the fixed dose combination of Vildagliptin and metformin (gradually titrated to a dose of 50 mg/500 mg twice daily or 50 mg/1000 mg twice daily) as initial therapy in drug- na&iuml;ve patients was evaluated. Vildagliptin/metformin 50 mg/1000 mg twice daily reduced HbA1c by - 1.82%, Vildagliptin/metformin 50 mg/500 mg twice daily by -1.61%, metformin 1000 mg twice daily by</p><p style="margin-left:19.55pt; margin-right:18.65pt; text-align:justify">-1.36% and Vildagliptin 50 mg twice daily by -1.09% from a mean baseline HbA1c of 8.6%. The decrease in HbA1c observed in patients with a baseline &ge;10.0% was greater.</p><p style="margin-left:19.55pt; margin-right:18.55pt; text-align:justify">A 24-week, multi-centre, randomised, double-blind, placebo-controlled trial was conducted to evaluate the treatment effect of Vildagliptin 50 mg once daily compared to placebo in 515 patients with type 2 diabetes and moderate renal impairment (N=294) or severe renal impairment (N=221). 68.8% and 80.5% of the patients with moderate and severe renal impairment respectively were treated with insulin (mean daily dose of 56 units and 51.6 units respectively) at baseline. In patients with moderate renal impairment Vildagliptin significantly decreased HbA1c compared with placebo (difference of -0.53%) from a mean baseline of 7.9%. In patients with severe renal impairment, Vildagliptin significantly decreased HbA1c compared with placebo (difference of -0.56%) from a mean baseline of 7.7%.</p><p style="margin-left:19.55pt; margin-right:18.75pt; text-align:justify">A 24-week randomised, double-blind, placebo-controlled trial was conducted in 318 patients to evaluate the efficacy and safety of Vildagliptin (50 mg twice daily) in combination with metformin (&ge;1500 mg daily) and glimepiride (&ge;4 mg daily). Vildagliptin in combination with metformin and glimepiride significantly decreased HbA1c compared with placebo.The placebo-adjusted mean reduction from a mean baseline HbA1c of 8.8% was -0.76%.</p><p style="margin-left:19.55pt; margin-right:18.65pt; text-align:justify">A 24-week randomised, double-blind, placebo-controlled trial was conducted in 449 patients to evaluate the efficacy and safety of Vildagliptin (50 mg twice daily) in combination with a stable dose of basal or premixed insulin (mean daily dose 41 units), with concomitant use of metformin (N=276) or without concomitant metformin (N=173). Vildagliptin in combination with insulin significantly decreased&nbsp; HbA1c compared with placebo. In the overall population, the placebo-adjusted mean reduction from a mean baseline HbA1c 8.8% was -0.72%. In the subgroups treated with insulin with or without concomitant metformin the placebo-adjusted mean reduction in HbA1c was -0.63% and -0.84%, respectively. The incidence of hypoglycaemia in the overall population was 8.4% and 7.2% in the Vildagliptin and placebo groups, respectively. Patients receiving Vildagliptin experienced no weight gain (+0.2 kg) while those receiving placebo experienced weight reduction (-0.7 kg).</p><p style="margin-left:19.55pt; margin-right:18.55pt; text-align:justify">In another 24-week study in patients with more advanced type 2 diabetes not adequately controlled on insulin (short and longer acting, average insulin dose 80 IU/day), the mean reduction in HbA1c when Vildagliptin (50 mg twice daily) was added to insulin was statistically significantly greater than with placebo plus insulin (0.5% vs. 0.2%). The incidence of hypoglycaemia was lower in the Vildagliptin group than in the placebo group (22.9% vs. 29.6%).</p><p style="margin-left:19.55pt; margin-right:18.4pt; text-align:justify">A 52-week multi-centre, randomised, double-blind trial was conducted in patients with type 2 diabetes and congestive heart failure (NYHA functional class I-III) to evaluate the effect of Vildagliptin 50 mg twice daily (N=128) compared to placebo (N=126) on left-ventricular ejection fraction (LVEF). Vildagliptin was not associated with a change in left-ventricular function or worsening of pre-existing CHF. Adjudicated cardiovascular events were balanced overall. There were more cardiac events in Vildagliptin treated patients with NYHA class III heart failure compared to placebo. However, there were imbalances in baseline cardiovascular risk favouring placebo and the number of events was low, precluding firm conclusions. Vildagliptin significantly decreased HbA1c compared with placebo (difference of 0.6%) from a mean baseline of 7.8% at week 16. In the subgroup with NYHA class III, the decrease in HbA1c compared to placebo was lower (difference 0.3%) but this conclusion is limited</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:19.55pt; margin-right:19.25pt; text-align:justify">by the small number of patients (n=44). The incidence of hypoglycaemia in the overall population was 4.7% and 5.6% in the Vildagliptin and placebo groups, respectively.</p><p style="margin-left:19.55pt; margin-right:0in; text-align:justify"><em><u>Cardiovascular risk</u></em></p><p style="margin-right:18.65pt; text-align:justify">A meta-analysis of independently and prospectively adjudicated cardiovascular events from 37 phase III and IV monotherapy and combination therapy clinical studies of up to more than 2 years duration (mean exposure 50 weeks for Vildagliptin and 49 weeks for comparators) was performed and showed that Vildagliptin treatment was not associated with an increase in cardiovascular risk versus comparators. The composite endpoint of adjudicated major adverse cardiovascular events (MACE) including acute myocardial infarction, stroke or cardiovascular death was similar for Vildagliptin versus combined active and placebo comparators [Mantel&ndash;Haenszel risk ratio (M-H RR) 0.82 (95% CI 0.61-1.11)]. A MACE occurred in 83 out of 9,599 (0.86%) Vildagliptin-treated patients and in 85 out of 7,102 (1.20%) comparator-treated patients. Assessment of each individual MACE component showed no increased risk (similar M-H RR). Confirmed heart failure (HF) events defined as HF requiring hospitalisation or new onset of HF were reported in 41 (0.43%) Vildagliptin-treated patients and 32 (0.45%) comparator- treated patients with M-H RR 1.08 (95% CI 0.68-1.70).</p><p>Table 8 Key efficacy results of Vildagliptin in placebo-controlled monotherapy trials and in add- on combination therapy trials (primary efficacy ITT population)</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#7a7a7a; height:58.15pt; vertical-align:top; width:197.05pt"><p style="margin-left:1.5pt; margin-right:.85pt"><strong>Monotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; placebo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; controlled studies</strong></p></td><td style="border-color:#7a7a7a; height:58.15pt; vertical-align:top; width:93.25pt"><p style="margin-left:1.4pt; margin-right:.6pt"><strong>Mean&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; baseline HbA</strong><strong>1c </strong><strong>(%)</strong></p></td><td style="border-color:#7a7a7a; height:58.15pt; vertical-align:top; width:114.0pt"><p style="margin-left:1.45pt; margin-right:.65pt"><strong>Mean&nbsp;&nbsp;&nbsp; change&nbsp;&nbsp; from baseline&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in</strong></p><p style="margin-left:1.45pt; margin-right:1.35pt"><strong>HbA</strong><strong>1c </strong><strong>(%) at&nbsp; week </strong><strong>24</strong></p></td><td style="border-color:#7a7a7a; height:58.15pt; vertical-align:top; width:114.0pt"><p style="margin-left:1.45pt; margin-right:.75pt"><strong>Placebo-corrected mean&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in HbA</strong><strong>1c </strong><strong>(%) at&nbsp; week </strong><strong>24 (95% CI)</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:30.55pt; vertical-align:top; width:197.05pt"><p style="margin-left:67.3pt; margin-right:5.95pt; text-indent:-59.65pt">Study 2301: Vildagliptin 50 mg twice daily (N=90)</p></td><td style="height:30.55pt; vertical-align:top; width:93.25pt"><p style="margin-left:39.1pt">8.6</p></td><td style="height:30.55pt; vertical-align:top; width:114.0pt"><p style="margin-left:46.35pt; margin-right:45.85pt; text-align:center">-0.8</p></td><td style="height:30.55pt; vertical-align:top; width:114.0pt"><p style="margin-left:0in; margin-right:16.2pt; text-align:right">-0.5* (-0.8, -0.1)</p></td></tr><tr><td style="border-color:#7a7a7a; height:30.55pt; vertical-align:top; width:197.05pt"><p style="margin-left:67.3pt; margin-right:5.95pt; text-indent:-59.65pt">Study 2384: Vildagliptin 50 mg twice daily (N=79)</p></td><td style="height:30.55pt; vertical-align:top; width:93.25pt"><p style="margin-left:39.1pt">8.4</p></td><td style="height:30.55pt; vertical-align:top; width:114.0pt"><p style="margin-left:46.35pt; margin-right:45.85pt; text-align:center">-0.7</p></td><td style="height:30.55pt; vertical-align:top; width:114.0pt"><p style="margin-left:0in; margin-right:16.2pt; text-align:right">-0.7* (-1.1, -0.4)</p></td></tr><tr><td style="border-color:#7a7a7a; height:16.85pt; vertical-align:top; width:197.05pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td><td style="height:16.85pt; vertical-align:top; width:93.25pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td><td colspan="2" style="height:16.85pt; vertical-align:top; width:228.0pt"><p style="margin-left:15.95pt">* p&lt; 0.05 for comparison versus placebo</p></td></tr><tr><td style="border-color:#7a7a7a; height:16.75pt; vertical-align:top; width:197.05pt"><p style="margin-left:21.55pt; margin-right:0in"><strong>Add-on </strong>/ <strong>Combination studies</strong></p></td><td style="height:16.75pt; vertical-align:top; width:93.25pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td><td style="height:16.75pt; vertical-align:top; width:114.0pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td><td style="height:16.75pt; vertical-align:top; width:114.0pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td></tr><tr><td style="border-color:#7a7a7a; height:30.55pt; vertical-align:top; width:197.05pt"><p style="margin-left:50.95pt; margin-right:18.25pt; text-indent:-31.0pt">Vildagliptin 50 mg twice daily + metformin (N=143)</p></td><td style="height:30.55pt; vertical-align:top; width:93.25pt"><p style="margin-left:39.1pt">8.4</p></td><td style="height:30.55pt; vertical-align:top; width:114.0pt"><p style="margin-left:46.35pt; margin-right:45.85pt; text-align:center">-0.9</p></td><td style="height:30.55pt; vertical-align:top; width:114.0pt"><p style="margin-left:0in; margin-right:16.2pt; text-align:right">-1.1* (-1.4, -0.8)</p></td></tr><tr><td style="border-color:#7a7a7a; height:30.55pt; vertical-align:top; width:197.05pt"><p style="margin-left:77.7pt; margin-right:.85pt; text-indent:-72.4pt">Vildagliptin 50 mg daily + glimepiride (N=132)</p></td><td style="height:30.55pt; vertical-align:top; width:93.25pt"><p style="margin-left:39.1pt">8.5</p></td><td style="height:30.55pt; vertical-align:top; width:114.0pt"><p style="margin-left:46.35pt; margin-right:45.85pt; text-align:center">-0.6</p></td><td style="height:30.55pt; vertical-align:top; width:114.0pt"><p style="margin-left:0in; margin-right:16.2pt; text-align:right">-0.6* (-0.9, -0.4)</p></td></tr><tr><td style="border-color:#7a7a7a; height:30.7pt; vertical-align:top; width:197.05pt"><p style="margin-left:46.5pt; margin-right:18.25pt; text-indent:-26.55pt">Vildagliptin 50 mg twice daily + pioglitazone (N=136)</p></td><td style="height:30.7pt; vertical-align:top; width:93.25pt"><p style="margin-left:39.1pt">8.7</p></td><td style="height:30.7pt; vertical-align:top; width:114.0pt"><p style="margin-left:46.35pt; margin-right:45.85pt; text-align:center">-1.0</p></td><td style="height:30.7pt; vertical-align:top; width:114.0pt"><p style="margin-left:0in; margin-right:16.2pt; text-align:right">-0.7* (-0.9, -0.4)</p></td></tr><tr><td style="border-color:#7a7a7a; height:30.55pt; vertical-align:top; width:197.05pt"><p style="margin-left:16.9pt; margin-right:15.2pt; text-indent:3.1pt">Vildagliptin 50 mg twice daily + metformin + glimepiride (N=152)</p></td><td style="height:30.55pt; vertical-align:top; width:93.25pt"><p style="margin-left:39.1pt; margin-right:0in">8.8</p></td><td style="height:30.55pt; vertical-align:top; width:114.0pt"><p style="margin-left:46.35pt; margin-right:45.85pt; text-align:center">-1.0</p></td><td style="height:30.55pt; vertical-align:top; width:114.0pt"><p style="margin-left:0in; margin-right:16.2pt; text-align:right">-0.8* (-1.0, -0.5)</p></td></tr><tr><td style="border-color:#7a7a7a; height:30.55pt; vertical-align:top; width:197.05pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td><td style="height:30.55pt; vertical-align:top; width:93.25pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td><td colspan="2" style="height:30.55pt; vertical-align:top; width:228.0pt"><p style="margin-left:86.65pt; margin-right:9.65pt; text-indent:-75.55pt">* p&lt; 0.05 for comparison versus placebo + comparator</p></td></tr></tbody></table><p style="text-align:justify"><u>Paediatric population</u></p><p style="margin-right:18.95pt; text-align:justify">The European Medicines Agency has waived the obligation to submit the results of studies with Vildagliptin in all subsets of the paediatric population with type 2 diabetes mellitus (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p style="margin-right:18.6pt; text-align:justify">Following oral administration in the fasting state, Vildagliptin is rapidly absorbed, with peak plasma concentrations observed at 1.7 hours. Food slightly delays the time to peak plasma concentration to 2.5 hours, but does not alter the overall exposure (AUC). Administration of Vildagliptin with food resulted in a decreased Cmax (19%). However, the magnitude of change is not clinically significant, so that Vildagliptin can be given with or without food. The absolute bioavailability is 85%.</p><p><u>Distribution</u></p><p style="margin-left:19.55pt; margin-right:18.65pt; text-align:justify">The plasma protein binding of Vildagliptin is low (9.3%) and Vildagliptin distributes equally between plasma and red blood cells. The mean volume of distribution of Vildagliptin at steady-state after intravenous administration (Vss) is 71 litres, suggesting extravascular distribution.</p><p><u>Biotransformation</u></p><p style="margin-right:18.65pt; text-align:justify">Metabolism is the major elimination pathway for Vildagliptin in humans, accounting for 69% of the dose. The major metabolite (LAY 151) is pharmacologically inactive and is the hydrolysis product of the cyano moiety, accounting for 57% of the dose, followed by the glucuronide (BQS867) and the amide hydrolysis products (4% of dose). In vitro data in human kidney microsomes suggest that the kidney may be one of the major organs contributing to the hydrolysis of Vildagliptin to its major inactive metabolite, LAY151. DPP-4 contributes partially to the&nbsp; hydrolysis&nbsp; of&nbsp; Vildagliptin&nbsp; based&nbsp; on&nbsp; an <em>in vivo </em>study using DPP-4 deficient rats. Vildagliptin is not metabolised by CYP 450 enzymes to any quantifiable extent. Accordingly, the metabolic clearance of Vildagliptin is not anticipated to be affected by co-medications that are CYP 450 inhibitors and/or inducers. <em>In vitro </em>studies demonstrated that Vildagliptin does not inhibit/induce CYP 450 enzymes. Therefore, Vildagliptin is not likely to affect metabolic clearance of co-medications metabolised by CYP 1A2, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1 or CYP 3A4/5.</p><p><u>Elimination</u></p><p style="margin-left:19.55pt; margin-right:18.55pt; text-align:justify">Following oral administration of [14C] Vildagliptin, approximately 85% of the dose was excreted into the urine and 15% of the dose is recovered in the faeces. Renal excretion of the unchanged Vildagliptin accounted for 23% of the dose after oral administration. After intravenous administration to healthy subjects, the total plasma and renal clearances of Vildagliptin are 41 and 13 l/h, respectively. The mean elimination half-life after intravenous administration is approximately 2 hours. The elimination half-life after oral administration is approximately 3 hours.</p><p><u>Linearity/non-linearity</u></p><p style="margin-left:19.55pt; margin-right:19.0pt; text-align:justify">The Cmax for Vildagliptin and the area under the plasma concentrations versus time curves (AUC) increased in an approximately dose proportional manner over the therapeutic dose range.</p><p style="text-align:justify"><u>Characteristics in specific groups of patients</u></p><p style="margin-left:19.55pt; margin-right:0in"><em><u>Gender</u></em></p><p style="margin-right:18.6pt; text-align:justify">No clinically relevant differences in the pharmacokinetics of Vildagliptin were observed between male and female healthy subjects within a wide range of age and body mass index (BMI). DPP-4 inhibition by Vildagliptin is not affected by gender.</p><p style="margin-left:19.55pt; margin-right:0in"><em><u>Elderly</u></em></p><p style="margin-right:18.75pt; text-align:justify">In healthy elderly subjects (&ge; 70 years), the overall exposure of Vildagliptin (100 mg once daily) was increased by 32%, with an 18% increase in peak plasma concentration as compared to young healthy</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:19.55pt; margin-right:18.5pt; text-align:justify">subjects (18-40 years). These changes are, however, not considered to be clinically relevant. DPP-4 inhibition by Vildagliptin is not affected by age.</p><p style="margin-left:19.55pt; margin-right:0in; text-align:justify"><em><u>Hepatic impairment</u></em></p><p style="margin-right:18.75pt; text-align:justify">The effect of impaired hepatic function on the pharmacokinetics of Vildagliptin was studied in patients with mild, moderate and severe hepatic impairment based on the Child-Pugh scores (ranging from 6 for mild to 12 for severe) in comparison with healthy subjects. The exposure to Vildagliptin after a single dose in patients with mild and moderate hepatic impairment was decreased (20% and 8%, respectively), while the exposure to Vildagliptin for patients with severe impairment was increased by 22%. The maximum change (increase or decrease) in the exposure to Vildagliptin is ~30%, which is not considered to be clinically relevant. There was no correlation between the severity of the hepatic disease and changes in the exposure to Vildagliptin.</p><p style="margin-left:19.55pt; margin-right:0in; text-align:justify"><em><u>Renal impairment</u></em></p><p style="margin-right:19.0pt; text-align:justify">A multiple-dose, open-label trial was conducted to evaluate the pharmacokinetics of the lower therapeutic dose of Vildagliptin (50 mg once daily) in patients with varying degrees of chronic renal impairment defined by creatinine clearance (mild: 50 to &lt;80 ml/min, moderate: 30 to &lt;50 ml/min and severe: &lt;30 ml/min) compared to normal healthy control subjects.</p><p style="margin-left:19.55pt; margin-right:18.7pt; text-align:justify">Vildagliptin AUC increased on average 1.4, 1.7 and 2-fold in patients with mild, moderate and severe renal impairment, respectively, compared to normal healthy subjects. AUC of the metabolites LAY151 and BQS867 increased on average about 1.5, 3 and 7-fold in patients with mild, moderate and severe renal impairment, respectively. Limited data from patients with end stage renal disease (ESRD) indicate that Vildagliptin exposure is similar to that in patients with severe renal impairment. LAY151 concentrations were approximately 2-3-fold higher than in patients with severe renal impairment.</p><p style="margin-right:18.75pt; text-align:justify">Vildagliptin was removed by haemodialysis to a limited extent (3% over a 3-4 hour haemodialysis session starting 4 hours post dose).</p><p style="margin-left:19.55pt; margin-right:0in; text-align:justify"><em><u>Ethnic group</u></em></p><p style="text-align:justify">Limited data suggest that race does not have any major influence on Vildagliptin pharmacokinetics.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:19.55pt; margin-right:18.7pt; text-align:justify">Intra-cardiac impulse conduction delays were observed in dogs with a no-effect dose of 15 mg/kg (7- fold human exposure based on Cmax).</p><p style="margin-left:19.55pt; margin-right:18.75pt; text-align:justify">Accumulation of foamy alveolar macrophages in the lung was observed in rats and mice. The no-effect dose in rats was 25 mg/kg (5-fold human exposure based on AUC) and in mice 750 mg/kg (142-fold human exposure).</p><p style="margin-left:19.55pt; margin-right:18.7pt; text-align:justify">Gastrointestinal symptoms, particularly soft faeces, mucoid faeces, diarrhoea and, at higher doses, faecal blood were observed in dogs. A no-effect level was not established.</p><p style="text-align:justify">Vildagliptin was not mutagenic in conventional <em>in vitro </em>and <em>in vivo </em>tests for genotoxicity.</p><p style="margin-left:19.55pt; margin-right:18.45pt; text-align:justify">A fertility and early embryonic development study in rats revealed no evidence of impaired fertility, reproductive performance or early embryonic development due to Vildagliptin. Embryo-foetal toxicity was evaluated in rats and rabbits. An increased incidence of wavy ribs was observed in rats in association with reduced maternal body weight parameters, with a no-effect dose of 75 mg/kg (10-fold human exposure). In rabbits, decreased foetal weight and skeletal variations indicative of developmental delays were noted only in the presence of severe maternal toxicity, with a no-effect dose of 50 mg/kg (9-</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:19.55pt; margin-right:18.6pt; text-align:justify">fold human exposure). A pre- and postnatal development study was performed in rats. Findings were only observed in association with maternal toxicity at &ge; 150 mg/kg and included a transient decrease in body weight and reduced motor activity in the F1 generation.</p><p style="margin-left:19.55pt; margin-right:18.6pt; text-align:justify">A two-year carcinogenicity study was conducted in rats at oral doses up to 900 mg/kg (approximately 200 times human exposure at the maximum recommended dose). No increases in tumour incidence attributable to Vildagliptin were observed. Another two-year carcinogenicity study was conducted in mice at oral doses up to 1,000 mg/kg. An increased incidence of mammary adenocarcinomas and haemangiosarcomas was observed with a no-effect dose of 500 mg/kg (59-fold human exposure) and 100 mg/kg (16-fold human exposure), respectively. The increased incidence of these tumours in mice is considered not to represent a significant risk to humans based on the lack of genotoxicity of Vildagliptin and its principal metabolite, the occurrence of tumours only in one species and the high systemic exposure ratios at which tumours were observed.</p><p style="margin-right:18.85pt; text-align:justify">In a 13-week toxicology study in cynomolgus monkeys, skin lesions have been recorded at doses &ge; 5 mg/kg/day. These were consistently located on the extremities (hands, feet, ears and tail). At 5 mg/kg/day (approximately equivalent to human AUC exposure at the 100 mg dose), only blisters were observed. They were reversible despite continued treatment and were not associated with histopathological abnormalities. Flaking skin, peeling skin, scabs and tail sores with correlating histopathological changes were noted at doses &ge; 20 mg/kg/day (approximately 3 times human AUC exposure at the 100 mg dose). Necrotic lesions of the tail were observed at &ge; 80 mg/kg/day. Skin lesions were not reversible in the monkeys treated at 160 mg/kg/day during a 4-week recovery period.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:19.55pt; margin-right:354.95pt">Lactose Anhydrous Microcrystalline Cellulose PH 102 Sodium Starch Glycolate Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.6pt; margin-right:433.55pt; text-align:center">not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:40.55pt; margin-right:0in">Do not store above 30&deg; C.</p><p style="margin-left:40.55pt; margin-right:202.35pt">Store in the original package in order to protect from moisture Keep out the sight and reach of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:19.55pt; margin-right:18.9pt">Vildagliptin are packed in Alu-Alu Blister Pack, available in a box of 3 blisters, 10 tablets per each blister.</p><p style="margin-left:19.55pt; margin-right:18.9pt">Vildagliptin are packed in Alu-Alu Blister Pack, available in a box of 6 blisters, 10 tablets per each blister.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
P.O. Box 6267
Jeddah 21442, Saudi Arabia. Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com Website: www.jamjoompharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>